Effective Date: October 1, 2021
INTRODUCTION
Tryptamine Therapeutics Ltd. (“Tryp,” “us,” “our,” or “we”) recognizes that your personal privacy is important to you. This Privacy Policy (“Privacy Policy”) describes how we collect, process, and share your Personal Data (defined below) through our website at www.tryptherapeutics.com (the “Site”) and when you otherwise interact with us (collectively, our “Services”). We also describe your rights and choices with respect to your Personal Data and other important information. Please read this Privacy Policy carefully.
This Privacy Policy does not apply to any data collected by third parties you may encounter through our Services, which have their own privacy policies. Please review the separate privacy policies of any third parties before you provide information to them. This Privacy Policy also does not include any information collected if you participate in a clinical trial, which will be subject to a separate privacy notice and consent process. However, if you create an account with us to express your interest in a clinical trial, the account creation is subject to this Privacy Policy.
CATEGORIES AND SOURCES OF PERSONAL DATA
The following describes how we process data relating to identified or identifiable individuals and households (“Personal Data”):
The categories of Personal Data we may collect and use include (these are examples may be subject to change):
Identity Data | Information such as your name; account details; user name and password; and your identity. |
Contact Data | Identity Data that relates to information about how we can communicate with you, such as email, phone numbers, and mailing addresses. |
Location Data | Information about your location, including data you provide to us, or location data we may infer from your IP address. |
Device/Network Data | Browsing history, search history, and information regarding your interaction with our website or an advertisement (e.g. IP Address, MAC Address, SSIDs or other device identifiers or persistent identifiers), online user ID, device characteristics (such as browser/OS version), web server logs, application logs, browsing data, first party cookies, third party cookies, web beacons, clear gifs, embedded pixels, and pixel tags. |
Commercial Data | Information about services we provide to you and about transactions you make with us, and similar information. |
Inference Data | Personal Data we may infer based on your interactions with us or any data we may receive about you from third parties, such as our inferences regarding your interests based on your interactions with our website any User Content you provide to us, or otherwise. |
Financial Data | Information such as bank account details or payment card information. |
Health Data | Information relating to your health, such as if you indicate that you have a particular medical condition. We may infer Health Data based on your interest in a particular clinical trial. |
User Content | Unstructured/free-form data that may include any category of Personal Data, e.g. data that you give us in free text fields such as comment boxes. Depending on the information you provide to us, this may include information relating to your health, which may be considered Special Category Data pursuant to various laws. |
Sources of Personal Data
We collect Personal Data from various sources, including:
Data you provide us | We receive Personal Data you provide to us, such as when you create a customer account, complete a form on our Site, or when you join our email list. |
Data we collect automatically | We collect Personal Data about or generated by any device you have used to access our Site. |
Data we receive from service providers & Agents | We may receive Personal Data from service providers or agents performing services on our behalf, such as service providers who provide corporate communications services to Tryp. |
Data we receive from aggregators and advertisers | We receive Personal Data from ad networks, behavioral advertising vendors, market research, and social media companies or similar companies that provide us with additional Personal Data such as Inference Data. |
Data we receive from social media companies | We receive Personal Data from Facebook and other social media companies who may transfer Personal Data to us when you interact with that social media company in connection with our Services. |
Data we create and infer | We, certain partners, social media companies, and third parties operating on our behalf create and infer Personal Data such as Inference Data based on our observations or analysis of other Personal Data processed under this Policy, and we may correlate this data with other data we process about you. In some cases, we may make inferences regarding your health if you express interest in a particular clinical trial, or based on other User Content you provide to us. We may combine any Personal Data about you that we receive from you and from third parties. |
HOW WE PROCESS PERSONAL DATA
When you access or use our Site
When you use our Site, we automatically collect and process Device/Network Data. We use this data as necessary to initiate or provide certain features or functions through our Site. In addition to Device/Network Data, we may also collect and process Contact Data, Identity Data and Inference Data that we collect, create, and/or receive (including through the use of cookies and similar technologies). We typically use this data as necessary in connection with certain legitimate business interests, such as ensuring the security of our Site and other technology systems, and analyzing the use of our Site, to help us make improvements.
When you register for an account with us
When you register for an account with us, we generally process Identity Data and Contact Data. We may process this Personal Data to provide you with information about upcoming clinical trials or other information about our Services.
Cookies and other tracking technologies
We use cookies, web pixels, and similar technologies on our Site. These technologies can be used to collect or create Identity Data, Device/Network Data, Contact Data, or Inference Data. Third parties may be allowed to view, edit, or set their own cookies, web pixels or place web beacons on our websites. Cookies and web beacons allow us and third parties to distinguish you from other users of our websites, and some of these technologies can be used by us and/or our third party partners to identify you across platforms, devices, sites, and services. Third parties may engage in targeted advertising using this data. We and authorized third parties may use cookies and similar technologies for the following purposes:
The use of these technologies by third parties may be subject to their own privacy policies and is not covered by this Privacy Policy, except as required by law.
When you contact us or submit information to us
We collect and process Identity Data, Contact Data, and any User Content you provide as necessary to address your request, fulfill the business purpose for which that information was provided, or for other related purposes.
How we Process Personal Data for Business Purposes
Service Provision and Contractual Obligations
We process any Personal Data as is necessary to provide our Services, to authenticate users who have accounts with us, and as otherwise necessary to fulfill our contractual obligations to you, and provide you with the information, features, and services you request.
Internal Processing and Service Improvement
We may use any Personal Data in connection with improving our Site and email communications, for customer service purposes, to understand what parts of our Service are most relevant, how you interact with our Site, and how our Site performs.
Security and Incident Detection
We may process any Personal Data we collect in connection with detecting security incidents, or to protect against, and respond to malicious, deceptive, fraudulent, or illegal activity.
Legal Compliance
We also process any Personal Data as necessary to comply with our legal obligations, such as where you exercise your rights under data protection law and make requests, for the establishment and defense of legal claims, or where we must comply with our legal obligations, lawful requests from government or law enforcement officials.
Aggregated data
We process Personal Data in order to identify trends (to create aggregated and anonymized data about our customers/users interests, use of our Services, and other similar information (“Aggregated Data”). We may pass Aggregated Data to certain third parties to give them a better understanding of our business and to improve our Site. Aggregated Data will not contain information from which you may be personally identified.
Other Business Purposes
If we process Personal Data in connection with our Service in a way not described in this Privacy Policy, we will process such information in accordance with the notice provided at the time of collection or in a manner that is necessary and proportionate to achieve the purpose for which the Personal Data was collected, or for another purpose that is compatible with the context in which the Personal Data was collected.
How we Process Personal Data for Commercial Purposes
Personalization & Consumer Profiles
In order to understand our customers’ preferences, and better recommend products and services to our prior customers, we may create a “Consumer Profile” by linking together and analyzing Personal Data collected in the following contexts:
We may also augment Consumer Profiles with Personal Data that we create (such as Inference Data) or that we receive from third parties. We use Consumer Profiles for our legitimate interests in market research and statistical analysis in connection with the improvement of our Services. We may also use this information for other Commercial Purposes.
Marketing Communications
Consistent with our legitimate business interests, we or our third-party partners may send you marketing and promotional communications if you sign up for such communications. We may also collect Device/Network Data and Contact Data so that we can determine whether you have opened an email or interacted with our communications, and we may generate Inference Data based on these interactions. We may also process this Personal Data for targeted advertising. However, where consent to processing is required by law, we will link and process this information only with appropriate consent.
Targeted Advertising
We may engage in targeted advertising. This form of advertising includes various parties and services providers, including third parties, engaged in the processing of Personal Data in connection with advertising. These parties may be able to identify you across sites, devices, and over time. The parties that control the processing of Personal Data for behavioral advertising may create or leverage information derived from personalization and profiling. In some cases, these parties may also develop and assess aspects of a profile about you to determine whether to advertise to you, and if ads you see are effective.
HOW WE SHARE PERSONAL DATA
Affiliates | We may share Personal Data internally with our current and future affiliated entities. |
Service Providers & Agents | In connection with our general business operations, product/service improvements, to enable certain features, and in connection with our other legitimate business interests and business purposes, we may share your Personal Data with service providers who provide certain services or process data on our behalf. For example, we use third parties to host our Site and email server, provide cloud storage, send certain emails, process credit card payments, deliver packages. These companies only have access to personal information needed to perform their functions, but may not use it for other purposes. |
Social Media Platforms | We may share certain Personal Data with current or future affiliated entities and trusted third parties for marketing, advertising, or other commercial purposes, and we may allow third parties (such as social media advertisers, ad exchanges, data management platforms, or ad servers) to operate on our Services and process data for targeted advertising. |
Corporate Events | Your Personal Data may be shared in the event that we go through a business transition, such as a merger, acquisition, liquidation, or sale of all or a portion of our assets |
Legal Disclosures | In limited circumstances, we may, without notice or your consent, access and disclose your Personal Data and any other information that we may have about you to the extent we believe such disclosure is legally required, to prevent or respond to a crime, to investigate violations of our Terms of Use or an agreement we have with you, or in the vital interests of us or any person. We may, in our sole discretion (but without any obligation), object to the disclosure of your Personal Data to such parties. |
If we otherwise intend to disclose your Personal Data to a third party, if required by applicable law, we will identify that third party and the purpose for the disclosure, and obtain your consent.
INTERNATIONAL TRANSFERS OF PERSONAL DATA
If you are located outside the US, your Personal Data may be transferred to and/or processed by Tryp or third parties in the US or another location, which may include locations outside of the European Economic Area (EEA) in connection with our Services. Some countries outside the EEA do not have laws that protect your privacy rights as extensively as those in the EEA. However, if we do transfer your Personal Data to other territories, we will put in place appropriate safeguards to ensure that your Personal Data are properly protected and processed only in accordance with this Privacy Policy. We may transfer Personal Data from the EEA to the US using the EU standard contractual clauses or other lawful mechanisms.
YOUR Rights and CHOICES
Marketing Communications
You can withdraw your consent to receive marketing communications by clicking on the unsubscribe link in an email. You can also withdraw your consent to receive marketing communications or any other consent you have previously provided to us by contacting us. To opt-out of the collection of information relating to email opens, configure your email so that it does not load images in our emails. Note that some non-marketing communications are not subject to general opt-out, such as communications related to your user account for this Site, transactions with Tryp and product and service updates.
Withdrawing Your Consent/Opt-Out
Where we are processing your Personal Data based on your consent, you may change your mind and withdraw your consent at any time. The consequence of you withdrawing consent might be that we cannot perform certain services for you.
Tracking
Certain third parties may track your Internet usage over time and across third party sites. Our Services do not respond to your browser’s do-not-track request. If you do not want information collected through the use of cookies, you can manage/deny cookies (and certain technologies) using your browser’s settings menu. You must opt out of third party services directly via the third party. For example, to opt-out of Google’s analytic and marketing services, visit Google Analytics Terms of Use, the Google Privacy Policy, or Google Analytics Opt-out.
Advertising
You may opt out or withdraw your consent to behavioral advertising. In some cases, we may be able to process third party opt-out requests directly, however in some cases, you must opt out of third party services directly via the third party. For example, to opt out of Google’s use of cookies, visit Google’s Ads Settings, here. If you wish to take steps to opt-out of tracking by certain online advertisers, you can visit the Digital Advertising Alliance’s opt-out page at http://www.aboutads.info/choic…;or the Network Advertising Initiative at www.networkadvertising.org/optout_nonppii.asp. You can limit or opt out of our processing for behavioral advertising by contacting us.
Other Data Rights
Depending on the location of your residence, you may have certain rights regarding your Personal Data. These may potentially include the right to make a written request to review any Personal Data we have about you that we have collected, used or disclosed, and the right to receive a copy of such Personal Data, or to have it deleted, and we will provide you with applicable data rights to the extent required by law. You may also have the right challenge the accuracy or completeness of your Personal Data in our records. If you successfully demonstrate that your personal information in our records is inaccurate or incomplete, we will amend the personal information as required.
ADDITIONAL RIGHTS AND DISCLOSURES: EU/EEA
Under the GDPR and analogous legislation, you may have the following rights, subject to your submission of an appropriately verified request:
Access: | You may have a right to know what Personal Data we collect, use, disclose, or sell, and you may have the right to receive a list of that Personal Data and a list of the third parties (or categories of third parties) with whom we have received or shared Personal Data, to the extent required and permitted by law. You may be able to access some of the Personal Data we hold about you directly through the account settings menu. |
Rectification: | You may correct any Personal Data that we hold about you to the extent required and permitted by law. You may be able to make changes to much of the information you provided to us using the account settings menu. |
Delete: | To the extent required by applicable law, you may request that we delete your Personal Data from our systems. We may delete your Personal Data entirely, or we may anonymize or aggregate your information such that it no longer reasonably identifies you. Contact us as part of your request to determine how your Personal Data will be erased in connection with your request. |
Data Export: | To the extent required by applicable law, we will send you a copy of your Personal Data in a common portable format of our choice. |
Objection: | You may have the right under applicable law to object to our processing of your Personal Data that we undertake without your consent in connection with our legitimate business interests (including any processing specified as such, or processed under this Privacy Policy for a Business Purpose). You may do so by contacting us. Note that we may not be required to cease, or limit processing based solely on that objection, and we may continue processing cases where our interests in processing are balanced against individuals’ privacy interests.You may also object to processing for direct marketing purposes. We will cease this processing upon your objection. |
Regulator Contact: | You may have the right to contact or file a complaint with regulators or supervisory authorities about our processing of Personal Data. To do so, please contact your local data protection or consumer protection authority. |
Submission and Verification of Requests
You may submit any of the above requests by emailing privacy@tryptherapeutics.com. We verify requests to ensure that the individual making the request is authorized to make that request, to reduce fraud, and to ensure the security of your Personal Data.
CHANGES TO OUR PRIVACY POLICY
We reserve the right to change our Privacy Policy from time to time. Any such changes will be posted on this page so that we can keep you informed about how we process your Personal Data. We recommend that you consult this page frequently so that you are aware of our latest Privacy Policy and can update your preferences if necessary. Your continued use of our Services shall constitute your acceptance of any revised Privacy Policy.
HOW TO CONTACT US
If you have any comments or questions about this Privacy Policy or privacy practices, please contact our team at privacy@tryptherapeutics.com.
Chief Financial Officer
Mr George is a Director at Bio101 Financial Advisory (‘Bio101’), a financial services firm providing outsourced CFO, taxation and company secretarial solutions to the biotechnology and healthcare sector. He has over 10 years of finance and commercial experience working with public and private companies in Australia and abroad. Mr George currently serves as CFO and Company Secretary for several ASX-listed, private companies and not-for-profits.
He holds a Bachelor of Commerce from the University of Melbourne, a Masters Degree in Professional Accounting from RMIT, a Certificate in Governance Practice from the Governance Institute of Australia and is a qualified Chartered Accountant.
Scientific Advisor
Professor Philippa Hay is a renowned academic psychiatrist with international recognition for her research on eating disorders and obesity. With over 500 scientific papers and significant contributions to clinical practice and treatment guidelines, she has influenced national and international standards.
Notably, she led the development of the Royal Australian and New Zealand College of Psychiatrists’ national guidelines and the EDP framework for Medicare-supported recovery in Australia. Awarded the ANZ Academy for Eating Disorders Lifetime Leadership Award and the RANZCP Senior Research Award, she is also the founding Editor-in-Chief of the Journal of Eating Disorders and a past-President of the Australian Academy for Eating Disorders.
Her current research includes clinical trials for anorexia nervosa, public health interventions, and the exploration of psychedelics in treatment. She serves as a principal reviewer for the Cochrane Library and frequently contributes to leading journals and publications.
Scientific Advisor
Professor David Castle is a distinguished psychiatric scholar, who most recently was appointed by the Tasmanian Government as Professor of Psychiatry at the University of Tasmania’s Centre for Mental Health Service Innovation, launched in partnership with the Tasmanian Department of Health.
Previously, he served as the Inaugural Scientific Director at the Centre for Complex Interventions and the Centre for Addictions and Mental Health at the University of Toronto, and as Professor of Psychiatry at the University of Melbourne. With a focus on mental health conditions such as schizophrenia, bipolar disorder, and OCD, he is known for his research on psychedelic treatments and body dysmorphic disorder.
Professor Castle has published over 900 works, reviews for numerous scientific journals, and has a strong track record in securing significant research funding.
Scientific Advisor
William Schmidt, PhD is a Scientific Advisor to Tryp Therapeutics.
Dr. Schmidt serves as an expert on pain medicine pharmaceutical development with pharmaceutical and biotech companies throughout North America, Europe, Asia, Latin America and Australia. He currently sits on the Scientific or Medical Advisory Boards of five biotech companies. Dr. Schmidt has received many awards throughout his career including the John J. Bonica award for the development of new analgesics and for his sustained contributions to the educational efforts of the Eastern Pain Association in 2014. He joined DuPont Pharmaceuticals where he helped to develop nalbuphine (Nubain®), naltrexone (Trexan®, ReVia®) and the oxycodone-ibuprofen formulation used in Combunox™. He also led the clinical teams in the development of alvimopan (Entereg®) and polmacoxib (Acelex®).
Dr. Schmidt earned a BA from the University of California, Berkeley and a PhD from University of California, San Francisco.
Scientific Advisor
Derek Ott, MD is a Scientific Advisor to Tryp Therapeutics.
Dr. Ott is an Associate Clinical Professor of psychiatry at the UCLA School of Medicine, Director of the UCLA Pediatric Neuropsychiatry Clinic and a psychiatric consultant for Westside and Frank D. Lanterman Regional Centers in Los Angeles. He is a board-certified physician in child, adolescent and adult psychiatry. Dr. Ott has particular expertise in the areas of neuropsychiatry, developmental disabilities, attention-deficit hyperactivity disorder and childhood psychosis. His private practice focuses on psychopharmacology in children, adolescents and adults.
Dr. Ott earned a BS in human biology from Stanford University. He then attended the University of Illinois Urbana-Champaign, where he earned an MS in neuroscience and an MD.
Scientific Advisor
Rachel Wevrick, PhD is a Scientific Advisor to Tryp Therapeutics.
Dr. Wevrick is a Professor in the Department of Medical Genetics at the University of Alberta. Her research is focused on the genetic, molecular and physiological basis of abnormal neurodevelopment, growth and metabolism in developmental disorders affecting children. Her specific areas of interest include Prader-Willi syndrome, Schaaf-Yang syndrome and other neurodevelopmental disabilities that are caused by genetic mutations.
Dr. Wevrick earned a PhD from the Department of Molecular and Medical Genetics, University of Toronto and completed post-doctoral fellowships in the Department of Genetics at the Hospital for Sick Children Research Institute and at the Howard Hughes Medical Institute, Stanford University School of Medicine.
Scientific Advisor
Joel Castellanos, MD is a Scientific Advisor to Tryp Therapeutics.
Dr. Castellanos is an Associate Professor in the Department of Anesthesiology at the UC San Diego School of Medicine. He also serves as Medical Director of Inpatient Rehabilitation. Dr. Castellanos has specific clinical interests in pelvic pain, complex regional pain syndrome, phantom limb pain and post-spinal cord injury pain syndromes. His research interests include altering nutrition as a means of treating chronic pain, neuromodulation for chronic painful conditions and the potential use of psychedelics for these conditions.
Dr. Castellanos completed residency training in physical medicine and rehabilitation at University of Michigan Medical School, where he also completed a two-year program in healthcare administration. Dr. Castellanos earned his medical degree from University of Toledo College of Medicine in Ohio. He is board-certified in physical medicine and rehabilitation and pain medicine.
Scientific Advisor
Daniel Clauw, MD, is a Scientific Advisor to Tryp Therapeutics.
Dr. Clauw is a Professor of anesthesiology, medicine (Rheumatology) and psychiatry at the University of Michigan. He serves as Director of the Chronic Pain and Fatigue Research Center. He joined the faculty at Georgetown University in 1990, and while there, founded the Georgetown Chronic Pain and Fatigue Research Center, and served as the Division Chief of Rheumatology, Immunology and Allergy, and Vice Chair of the Department of Medicine. Since moving to UM in 2001, Dr. Clauw has continued his commitment to the clinical care and research into overlapping conditions such as Fibromyalgia, Gulf War Illnesses, and Interstitial Cystitis, just to name a few. Dr. Clauw has become an internationally known expert in chronic pain, and especially the central nervous system contributions to chronic pain states, performing past or ongoing work in conditions such as low back pain, osteoarthritis, vulvodynia, endometriosis, irritable bowel syndrome and temporomandibular joint disorder.
Dr. Clauw attended the University of Michigan for both undergraduate and medical school studies and then completed his Internal Medicine residency and Rheumatology Fellowship at Georgetown University.
Chairman, Scientific Advisory Board
Robin Carhart-Harris serves as Chairman of the Scientific Advisory Board for Tryp Therapeutics.
Dr. Carhart-Harris is the Ralph Metzner Distinguished Professor in Neurology and Psychiatry at the University of California, San Francisco. He is also the Director of the Psychedelics Division within the translational neuroscience center, Neuroscape, at UCSF. Dr. Carhart-Harris founded the Centre for Psychedelic Research at Imperial College London in April 2019, the first of its kind. He has designed human brain imaging studies with LSD, psilocybin, MDMA and DMT; a clinical trial of psilocybin for treatment-resistant depression; a double-blind randomized controlled trial comparing the effects of psilocybin and the SSRI escitalopram on depression that was published in the New England Journal of Medicine; and a multimodal imaging study in first-time users of psilocybin.
Dr. Carhart-Harris earned a BSc in applied psychology and computing from Bournemouth University, an MA in psychoanalysis and contemporary science from Brunel University, and a PhD in psychopharmacology from the University of Bristol. He has published over 100 scientific papers and in 2021 was listed in Time Magazine’s “100 Next,” a list of 100 rising stars shaping the future.
Non-Executive Director – B.Comm, MAICD
Clarke is a Financial Adviser and Capital Markets Specialist with over 20 years’ experience in the Financial Services Industry in Australia and the United Kingdom.
Clarke has experience in structuring, operations and risk management of institutional exotic derivatives in the United Kingdom with Morgan Stanley International Limited and has been a Derivatives Manager, responsible for establishing and managing derivatives trading desks for several Australian based stockbroking firms.
Clarke brings to Exopharm his extensive experience providing corporate advisory services for companies listed on the Australian Securities Exchange (ASX) across a variety of industries, with a particular focus on growth opportunities in the Biotechnology, Technology, Industrial and Resource industries, providing them with advice on business models & strategy, structuring of pre-IPO and IPO fund raisings, reverse takeovers, capital raisings, mergers and acquisitions, investor relations and capital markets advice.
Clarke also services institutional, wholesale and retail clients, advising on ASX investments, share portfolios, derivatives, and identification of early-stage opportunities across a variety of industries and sectors.
Clarke is a Founding Director of AMG Acquisition Corp, a publicly listed company on the Toronto Venture Exchange.
Clarke holds a Bachelor of Commerce degree from the University of Western Australia and is a Member of the Australian Institute of Company Directors (AICD).
Chairman
Mark is Founder and Managing Director at 1861 Capital and has been an investor in Exopharm since the IPO in 2018. Mark has a Bachelor of Commerce from the University of Western Australia and is Non-Executive Chairman of Neurotech International (ASX: NTI), a drug development company focused on utilising NTI164 in the treatment for paediatric neurological disorders including Autism Spectrum Disorder (ASD).
Non Executive Director – B.Comm
Mr Ntoumenopoulos is the Managing Director at Twenty 1 Corporate, an Australian-based corporate advisory firm.
He has extensive experience in financial markets, with over 20 years of raising capital and providing corporate advisory services. Additionally, he has served as a director of ASX listed companies for more than 7 years.
Mr Ntoumenopoulos was a founding director of both ResApp Health Ltd (ASX:RAP), which was acquired by Pfizer, and Race Oncology (ASX:RAC). Currently, he serves as a non-executive director at TrivarX Limited (ASX:TRI).
If elected, Mr Ntoumenopoulos will be considered by the Board (including the incoming Directors with Mr Ntoumenopolous abstaining) to be an independent Director. Mr Ntoumenopoulos is not considered by the Board to hold any interest, position or relationship that might influence, or reasonably be perceived to influence, in a material respect his capacity to bring an independent judgement to bear on issues before the Board and to act in the best interests of the entity as a whole rather than in the interests of an individual security holder or other party. Mr Ntoumenopoulos does not currently hold any other material directorships, other than as disclosed in this Prospectus.
Non Executive Director
Gage Jull serves as a Chairman of Tryp Therapeutics.
Gage is Executive Chairman of Arrow Exploration, a TSX-V and London AIM listed oil and gas exploration and production Company (TSX-V; AIM: AXL). Arrow has grown production, cleaned up its balance sheet and is growing its cashflow. Prior to Arrow, Gage was a Co-Founder and Chairman of Bordeaux Capital Inc., a Toronto-based mergers & acquisitions advisory firm focused on emerging companies in the natural resources and other sectors. Before Bordeaux Capital, Mr. Jull was a Managing Director, Corporate Finance at Mackie Research Capital Corp., an investment banking and securities brokerage firm. Mr. Jull has acted as lead underwriter on numerous cross border equity and debt offerings involving energy assets around the world, with capital sourced in Canada, the U.S. and the U.K. At Prudential Bache, Mr. Jull was the lead banker on the $40 million cross border IPO of Quadra Logic Technologies, a Vancouver based pharmaceutical company. He has completed over 200 financings and M&A transactions in the course of his career.
Mr. Jull holds a BSc degree from the University of Toronto, an MBA from the University of Western Ontario, and holds both PEng and CFA designations.
Company Secretary
David is a Director and Principal of the Automic Group. As a Senior Executive, Company Secretary and Director of ASX Listed Entities and Professional Services organisations, David has over 25 years of experience within this field, in a diverse range of industries.
David is a Chartered Accountant, Fellow of the Financial Services Institute of Australasia, Fellow of the Governance Institute of Australia, Justice of the Peace, Registered Tax Agent and holds a Bachelor of Economics (Finance and Accounting) from Macquarie University.
With over 25 years in finance and accounting, initially qualifying with Price Waterhouse in their Business Services and Corporate Finance Divisions, David has been CFO, Company Secretary and/or Director for numerous ASX listed and unlisted public and private companies, in a range of industries including energy retailing, software as a service, transport, financial services, mineral exploration, technology, automotive, software development wholesale distributions, retail, biotechnology and healthcare.
VP, Drug Development
Peter Guzzo, PhD serves as Vice President of Drug Development at Tryp Therapeutics.
Pete served as Director of Drug Discovery at Curia (formerly AMRI) for nearly 20 years where he led drug discovery teams from project conception through clinical trials. While at Curia, Pete developed products and intellectual property in the areas of CNS, oncology and gastrointestinal diseases. Pete co-founded and served as CEO at ConSynance Therapeutics, a clinical-stage drug development company pursuing treatments for rare diseases.
Pete earned a BS in chemistry from Assumption College and a PhD in organic chemistry from the University of Notre Dame. He is an inventor on 43 patents, has co-authored 47 scientific publications, and has presented nearly 30 invited lectures.
President & Chief Scientific Officer – Ph.D., MSIB.
Jim Gilligan currently serves as Chief Executive Officer, President and Chief Scientific Officer of Tryp.
Jim received his Ph.D in pharmacology and Toxicology from the University of Connecticut. He pursued his post-doctoral fellowship at the Roche Institute of Molecular Biology. Later in his career he returned to Seton Hall University where he earned an MBA in International Business.
Jim is a scientist, entrepreneur, executive, and business development specialist who has over 35 years in the pharmaceutical industry and co-founded and helped lead multiple bio-pharma and bio-tech companies, including Tryp, Tarsa Therapeutics, Herborium Inc., and Unigene Labs, where he oversaw the entire spectrum of drug development activities, including pharmacology and preclinical activities, CMC, clinical Phase I-III, as well as US and international regulatory strategies. Jim is a co-author on several manufacturing and formulation patents and has been featured in journal articles on novel therapeutic peptides and their clinical utility. He has executed numerous feasibility and licensing deals within the pharmaceutical industry, working frequently with investment bankers, venture capitalists, and brokers.
Chief Medical Officer
Michael Silverman, MD serves as the Chief Medical Officer of Tryp.
Michael has over 30 years of experience in clinical development in biotech including product development strategy, clinical/regulatory planning and operations, business strategic analysis and planning, and technical assessment and recommendations. Additionally, Michael has served as President of BioStrategics Consulting Ltd. since 1999.
Michael received his BS from the University of Illinois and his MD from the University of Chicago Pritzker School of Medicine.
Chief Business Officer
BA (Hons), CFA (UK)
Mr Molloy has 25 years of experience creating, advising and investing in private and public companies, with a particular focus on the healthcare sector. He was previously the founder and CEO of Edison Group where he spent 15 years building the company into an international brand with a global team in excess of 100 people, recognized for its world class equity research platform, advisory services, and deep sector expertise. He remains a Director and principle shareholder of Edison.
Mr Molloy is also the co-founder of various other companies including, most recently, Tarus Therapeutics, an immune-oncology company which was acquired by a NASDAQ listed biotech in July 2022. Mr Molloy’s earlier career includes a successful period as an institutional investor, most notably at Hermes Investment Management in London, managing a healthcare and technology focused small/mid-cap portfolio, and with a close involvement in Hermes’ shareholder activism initiatives.
Mr Molloy graduated from Exeter University (UK) with a degree in Economics and is an alumni of London Business School. He holds the CFA (UK) and FINRA Series 7.
Chief Executive Officer
Jason Caroll currently serves as Chief Executive Officer of Tryp.
Jason brings a wealth of experience as a highly regarded life sciences executive, with an impressive 32-year career in the industry. In addition to his most recent role as Managing Director of iNova Pharmaceuticals Philippines, his extensive background includes leadership roles at industry giants Johnson & Johnson, Janssen Pharmaceutica, and Bristol-Myers Squibb.
Jason received his B.Sc. in Organic Chemistry from Flinders University of South Australia and completed his Master of Business Administration in Technology Management from Deakin University.
Jason has managed roles of increasing responsibility in operations (Pharmaceutical Production Management), sales & marketing (Specialist Medical Representative, Product Management, Sales & Marketing Management & Business Unit Director) and business development (Early Product Development Lead, Associate Director of Market Access, Associate Director of Asia Regional Business Development and Business Licensing & Acquisition). His first country leadership role was as General Manager of Janssen Pharmaceutica Philippines, followed by Managing Director of One J&J Vietnam (including additional responsibilities as SEA Board representative of Janssen Pharmaceuticals Asia-Pacific and SEA Marketing Director of Immunology & Oncology and Global Board membership of the J&J Sustainability Council).
He has expertise across pharmaceuticals, biologics, medical devices, OTC & consumer medicines and is considered to be a turnaround specialist and outstanding people leader. Within his most recent role, Jason built a strong leadership team that increased iNova Pharmaceuticals Philippines sales 3 fold during his 5 year tenure.
Chief Financial Officer
Jim O’Neill – BBA, CPA and CA
Jim O’Neill currently serves as Chief Financial Officer of Tryp.
Jim has over 30 years of experience as a finance executive with publicly listed and private multi-national businesses. Most recently, he founded and serves as president of O’Neill & O’Neill Services Corp. providing financial consulting services including CFO and corporate secretarial services to TSXV and CSE listed companies.
Jim received his bachelor’s in business administration from Wilfrid Laurier University and holds a CPA and CA from the Chartered Professional Accountants of Ontario.